Observational studyScientific reports2025
Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ampicillin/sulbactam (ABPC/SBT) and piperacillin/tazobactam (PIPC/TAZ) are important beta-lactam/beta-lactamase inhibitor combinations. Recently, PIPC/TAZ has been reported to decrease serum potassium level (SPL). To test the hypothesis that ABPC/SBT also has the same impact, we evaluated the change in SPL by ABPC/SBT administration and compared with that by PIPC/TAZ. A retrospective, observational propensity-score matched cohort study was performed using data between 2020 and 2022. After subject selection, multiple regression analysis was conducted to identify risk factors associated with decrease in SPL. Baseline SPL, duration of ABPC/SBT or PIPC/TAZ administration, and female sex were identified as significant risk factors. Using the factors that potentially influence SPL, propensity score matching was performed, and the decrease in SPL was compared between the propensity score-matched cohorts (ABPC/SBT: n = 59, PIPC/TAZ: n = 59). The change in SPL was not significantly different between the two cohorts (- 0.28 ± 0.47 mEq/L vs. - 0.35 ± 0.51 mEq/L, P = 0.443). In addition, the percent decrease in SPL (10.7 ± 7.0% vs. 11.0 ± 9.7%, P = 0.822) and the incidence of hypokalemia (25.4% vs. 27.1%, P = 1.000) were not significantly different. ABPC/SBT decreases SPL comparable to PIPC/TAZ, with a clinically significant effect. Careful monitoring of SPL is necessary when patients with identified risk factors are treated with ABPC/SBT or PIPC/TAZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.